UNASSIGNED: Thirty-four subjects with symptomatic @entity3657 ( @entity3657 ) or critical limb ischmeia (CLI) who were experiencing @entity158 , @entity102 resting @entity158 , @entity1183 , and @entity63 lower leg/foot ulceration were randomized into 2 treatment groups. MATERIALS AND METHODS: Eighteen of these @entity1 received treatment with @entity101 ( @entity101 ) 60 minutes twice daily for 16 weeks, and 16 subjects received standard care consisting of an exercise regimen of walking for 20 minutes twice daily for 16 weeks. The @entity101 device delivers bilateral pressures of 120 mm Hg. Cycle times provide sequential compression for 4 seconds (+/- 0.5 seconds) followed by a 16-second rest period (+/- 3.0 seconds), resulting in a 20-second cycle or 3 cycles per minute. The study was designed to measure @entity1 -centered outcomes. The primary endpoint was @entity4464 ( @entity4464 ), defined as time to maximally tolerated @entity158 . Secondary endpoints included change in resting ankle brachial index, @entity1066 , relief of resting/wound @entity158 , and quality of life (QoL) index. Age (73.7 years vs 72.7 years), baseline PWTs (1-6 minutes), and risk factors were similar in both treatment groups. RESULTS: At 4 weeks, the percent change from baseline in @entity4464 did not vary significantly between treatment groups (17.8% for @entity101 and 17% for standard care). After 8 weeks, the percent change in @entity4464 for the @entity101 group was 41% compared to 32% for the group receiving standard care (P = 0.062). At the 16-week time point the percent change from baseline in @entity4464 was significantly different between treatment arms (35.5% for the standard care group and 54.7% for the group receiving @entity101 [P = 0.043]). The mean reduction in wound surface area was 57% and 71% at 12 weeks and 16 weeks, respectively, for the @entity101 group, compared to 45% and 56% for the control group. The @entity101 group reported significantly greater @entity158 relief at the 12-week (P = 0.044) and 16- week (P = 0.038) time points. Compared to the control group, the @entity101 group reported improvement in @entity1 -centered outcomes such as physical function and @entity158 . These differences were statistically significant (P less than 0.05) at the 16- week evaluation period. CONCLUSION: Therapy consisting of @entity101 for 2 hours daily for a period of 16 weeks significantly improved @entity4464 , reduced resting @entity158 , and improved healing rates, physical function, and @entity158 . There were no devicerelated complications, allowing for long-term use. This study further supports that @entity101 is safe and effective and should be considered for @entity1 who are not candidates for endovascular or surgical procedures. Furthermore, @entity101 offers an excellent alternative for the palliative care of @entity1 with @entity3657 and @entity4218 .

Effect of High-pressure, Intermittent Pneumatic Compression for the Treatment of @entity3657 and XXXX in @entity1 Without a Surgical Option.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1183 :: ('MESH:D006987', 'Disease') :: ['numbness'] @entity101 :: ('MESH:D006973', 'Disease') :: ['high-pressure, intermittent pneumatic compression', 'HPIPC'] @entity3657 :: ('MESH:D058729', 'Disease') :: ['PAD', 'peripheral arterial disease'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer healing'] @entity4218 :: ('MESH:D017880', 'Disease') :: ['CLI symptoms'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'bodily pain', 'claudication pain'] @entity4464 :: ('MESH:D013009', 'Disease') :: ['PWT', 'peak walking time']
@entity63 :: (MESH:D007511,Disease) :: ['Critical Limb Ischemia']
